Respiratory syncytial virus (RSV) is the most common cause of infant hospitalizations and severe RSV infections are a significant risk factor for childhood asthma. The pathogenic mechanisms responsible for RSV induced immunopathophysiology remain elusive. Using an age-appropriate mouse model of RSV, we show that IL-33 plays a critical role in the immunopathogenesis of severe RSV, which is assoc...

Viral bronchiolitis is one of the leading causes for hospitalization of infants in the world and causes an estimated one million deaths per year worldwide. Respiratory syncytial virus (RSV) is associated with the majority of cases. During the last few years it has become increasingly clear that T cells contribute to the abnormal regulation of the immune response in viral diseases since these ce...

BACKGROUND Respiratory syncytial virus (RSV) pneumonia after hematopoietic cell transplant (HCT) is associated with severe morbidity. Although RSV RNA has been detected in serum from patients with RSV lower respiratory disease (LRD) after HCT, the association with clinical outcomes has not been well established in multivariable models. Additionally, the role of antiviral treatment in HCT recipi...

This article explores the home health nurse's role in preventing respiratory syncytial virus (RSV) among premature infants. Thousands of children infected with RSV require hospitalization each year. Consistent contact with the infant alerts the nurse to subtle signs and symptoms of RSV infection, which may include nasal congestion, cough, low-grade fever, and malaise. By developing patient and ...

Abstract Respiratory syncytial virus (RSV) is an RNA that belongs to the Pneumovirus genus of Paramyxoviridae family. The aim this study was evaluate expressions inducible nitric oxide synthetase (iNOS), CD3 (pan T cells), and CD8 (cytotoxic cells) in lamb lungs naturally infected with RSV using immunohistochemistry (IHC). For purpose, 100 pneumonic 10 control lung tissue samples were taken fro...

RSV is a major cause of morbidity and mortality worldwide. Although no treatment or vaccine currently exists, RSV therapeutics and preventative strategies are being evaluated in clinical trials, including phase 3 trials. Despite great prospects, the regulatory pathways of novel RSV therapeutics have been defined insufficiently. Here we report the results from the ReSViNET 2nd High–level expert ...

Background. A better understanding of the characteristics and outcomes of adult patients hospitalized with RSV as compared to influenza infection is needed. Methods. We conducted a retrospective cohort study of adult patients admitted to four hospitals in Toronto, Canada, between September 2012 and June 2013 with RSV or influenza infection diagnosed by RT-PCR. Main outcomes were hospital length...

OBJECTIVE To determine the effects of age and respiratory syncytial virus (RSV) antibody status on frequency and severity of RSV infections in children with underlying heart or lung disease. DESIGN Cohort study conducted during two consecutive RSV seasons. SETTING Ambulatory patients at eight Canadian pediatric tertiary care centers. METHODS Subjects under 3 years old with underlying hear...

BACKGROUND Respiratory syncytial virus (RSV) causes significant pediatric morbidity and is the most common cause of bronchiolitis. Bronchiolitis hospitalizations declined among US infants from 2000‒2009; however, rates in infants at high risk for RSV have not been described. This study examined RSV and unspecified bronchiolitis (UB) hospitalization rates from 1997‒2012 among US high-risk infant...